Lessons learned from a decade of EUS(-FNA) staging in esophageal and GEJ carcinoma: towards a selective staging strategy
Diseases of the Esophagus · 2026-11-02 · 39 (6)
DOI: 10.1093/dote/doag128 ↗Abstract
Abstract Endoscopic ultrasonography with fine-needle aspiration (EUS(-FNA)) is recommended by current guidelines as part of the staging for esophageal and gastro-esophageal junction (GEJ) carcinoma, yet its incremental value over modern 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) remains uncertain. This Lessons Learned article reflects on over a decade of EUS(-FNA) and FDG-PET staging in 402 patients with potentially curable esophageal or GEJ carcinoma at a high-volume tertiary referral center. In 91.3% of patients, EUS(-FNA) did not alter the radiation field as would have been defined by FDG-PET. EUS(-FNA) resulted in an expansion of the radiation field in 4.5% and reduction in 4.2% of patients. Squamous cell carcinoma showed more than two-fold greater likelihood of radiation field modification. Among 193 patients classified as FDG-PET non-suspicious for malignant lymph nodes (LNs), EUS-FNA identified malignant LNs in eight patients (4.1%), which influenced the radiation field. In 5 of 402 patients (1.2%) a malignant LN was detected with EUS-FNA in a station that would not have routinely been resected surgically. In patients planned for neoadjuvant or definitive chemoradiotherapy (CRT), LN staging is of direct therapeutic consequence: underestimation of nodal disease may result in geographic miss, while overestimation leads to unnecessary irradiation. In contrast, in patients treated with perioperative 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) followed by surgical lymphadenectomy, most involved LN stations are routinely addressed surgically, limiting the added value of EUS(-FNA) for treatment planning. Therefore, we view EUS(-FNA) as a selective staging tool in patients planned for neoadjuvant or definitive CRT, rather than a procedure applied routinely to all patients.
EUVIMED